Literature DB >> 3005516

Localization of cytomegalovirus proteins and genome during fulminant central nervous system infection in an AIDS patient.

C A Wiley, R D Schrier, F J Denaro, J A Nelson, P W Lampert, M B Oldstone.   

Abstract

Approximately one-half of autopsied acquired immune deficiency syndrome (AIDS) patients demonstrate probable human cytomegalovirus (CMV) infection of the central nervous system (CNS). Because CMV in brain tissue or cerebrospinal fluid is difficult to culture, we used antisera, and radioactive probes to diagnose CMV infection in the brain of an autopsied AIDS patient, who died of a fulminant CNS and systemic infection with CMV, suggesting a complete seeding of the ependymal regions possibly followed by a uniform ventriculofugal spread of the virus deep into the parenchyma. Cytomegalic cells were observed in optic nerve, retina, ependymal and subependymal regions of the brain and in the motor (but not sensory) root-CNS junctions. Immunocytochemistry demonstrated viral antigen predominantly in cytomegalic cells, which also stained positively for glial fibrillary acidic protein, S-100, or neuron-specific enolase, but not a common leukocyte antigen. Virions were visible in these cells examined by electron microscopy. No viral replication was observed in pineocytes, pituicytes or the choroid plexus. Morphologically normal cells that were CMV antigen-negative proved to be infected after in situ hybridization with well-defined human CMV DNA fragments. Hence, morphologically normal glia and neurons show restricted replication of CMV, indicating that such cells may be latently infected.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3005516     DOI: 10.1097/00005072-198603000-00003

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  44 in total

1.  A strong negative transcriptional regulatory region between the human cytomegalovirus UL127 gene and the major immediate-early enhancer.

Authors:  C A Lundquist; J L Meier; M F Stinski
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Colocalisation of human immunodeficiency virus and human cytomegalovirus infection in brain autopsy tissue from AIDS patients.

Authors:  I M Balluz; M A Farrell; E Kay; M J Staunton; J N Keating; O Sheils; S L Cosby; M J Mabruk; B J Sheahan; G J Atkins
Journal:  Ir J Med Sci       Date:  1996 Apr-Jun       Impact factor: 1.568

Review 3.  Diagnosis of cytomegalovirus infection: a review.

Authors:  D Pillay; P D Griffiths
Journal:  Genitourin Med       Date:  1992-06

4.  Cytomegalovirus cell tropism, replication, and gene transfer in brain.

Authors:  A N van Den Pol; E Mocarski; N Saederup; J Vieira; T J Meier
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

5.  Disseminated cytomegalovirus infection in immunodeficient rhesus monkeys.

Authors:  G B Baskin
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

6.  Dementia and ataxia in a patient with AIDS.

Authors:  G L Clark; H V Vinters
Journal:  West J Med       Date:  1987-01

7.  Cytomegalovirus infection in gastrointestinal tracts of patients infected with HIV-1 or AIDS.

Authors:  N D Francis; A W Boylston; A H Roberts; J M Parkin; A J Pinching
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

8.  Cytomegalovirus (CMV) disease of the brain in AIDS and connatal infection: a comparative study by histology, immunocytochemistry and in situ DNA hybridization.

Authors:  M Schmidbauer; H Budka; W Ulrich; P Ambros
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

9.  Immune predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group.

Authors:  R D Schrier; W R Freeman; C A Wiley; J A McCutchan
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  Borna disease: association with a maturation defect in the cellular immune response.

Authors:  K M Carbone; S W Park; S A Rubin; R W Waltrip; G B Vogelsang
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.